Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT ID: NCT05059522
Last Updated: 2025-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
68 participants
INTERVENTIONAL
2021-09-29
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
NCT03317496
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
NCT04260802
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
NCT01772004
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
NCT04305249
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
B9991001 - NCT02603432 B9991003 - NCT02684006 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Avelumab monotherapy as specified by sub-study protocol B9991001C
Avelumab
oral
Arm 2
Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
Avelumab
oral
CMP 001
IT (intratumoral) or SC (subcutaneous)
Utomilumab
IV infusion
PF04518600
IV infusion
Arm 3
Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
Avelumab
oral
Lorlatanib
oral
Arm 4
Avelumab monotherapy as specified by sub-study protocol B9991009C
Avelumab
oral
Arm 5
Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
Avelumab
oral
Pemetrexed
IV (intravenous) infusion
Arm 6
Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
Avelumab
oral
Talazoparib
oral
Arm 7
Avelumab in combination with Axitinib as specified by sub-study B9991027C.
Avelumab
oral
Axitinib
oral
Arm 8
Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
Avelumab
oral
Talazoparib
oral
Arm 9
Avelumab in combination with Axitinib as specified by sub-study protocol B9991003C
Avelumab
oral
Axitinib
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avelumab
oral
Lorlatanib
oral
Talazoparib
oral
Pemetrexed
IV (intravenous) infusion
Axitinib
oral
CMP 001
IT (intratumoral) or SC (subcutaneous)
Utomilumab
IV infusion
PF04518600
IV infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants must agree to follow the reproductive criteria.
3. Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
Exclusion Criteria
2. Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Highlands Oncology Group, PA
Fayetteville, Arkansas, United States
Highlands Oncology Group, PA
Rogers, Arkansas, United States
Highlands Oncology Group, PA
Springdale, Arkansas, United States
UCLA Hematology/Oncology
Los Angeles, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
MSK Basking Ridge
Basking Ridge, New Jersey, United States
MSK Monmouth
Middletown, New Jersey, United States
MSK Bergen
Montvale, New Jersey, United States
MSK Commack
Commack, New York, United States
MSK Westchester
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York, United States
Memorial Sloan Kettering Cancer Center 53rd street.
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
MSK Nassau
Uniondale, New York, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Macquarie University
North Ryde, New South Wales, Australia
Mater Hospital Sydney
Wollstonecraft, New South Wales, Australia
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Grand Hôpital de Charleroi
Gilly, Hainaut, Belgium
UZ Gent
Ghent, Oost-vlaanderen, Belgium
Cross Cancer Institute
Edmonton, Alberta, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site
Kingston, Ontario, Canada
Aalborg Universitetshospital, Syd
Aalborg, North Denmark, Denmark
Institut de Cancérologie de Lorraine Alexis Vautrin
Vandœuvre-lès-Nancy, Lorraine, France
Országos Onkológiai Intézet
Budapest, , Hungary
Rabin Medical Center
Petah Tikva, Central District, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, Italy
IRCCS Istituto Clinico Humanitas
Rozzano, Milano, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi
Ancona, , Italy
Oita University Hospital
Yufu, Oita Prefecture, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Japanese Foundation for Cancer Research
Koto, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, , Japan
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico
Oaxaca Site Management Organization S.C.
Oaxaca City, , Mexico
Auckland City Hospital
Auckland, , New Zealand
Centralny Szpital Kliniczny MSWiA w Warszawie
Warsaw, , Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, , Poland
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
Omsk, Omsk Oblast, Russia
Private Medical Institution "Euromedservice"
Pushkin, Sankt-Peterburg, Russia
GBUZ SK Pyatigorsk Interdistrict Oncology dispensary
Pyatigorsk, Stavropol Kray, Russia
Moscow Scientific Research Oncology Institute n.a. P.A. Hertzen
Moscow, , Russia
FBIH "Privolzhskiy Regional Medical Center" of FMBA
Nizhny Novgorod, , Russia
SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan
Ufa, , Russia
Institute for Oncology and Radiology of Serbia
Belgrade, , Serbia
Gachon University Gil Medical Center
Namdong-gu, Incheon-gwangyeoksi [incheon], South Korea
National Cancer Center
Goyang-si, Kyǒnggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, South Korea
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Asan Medical Center
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], Spain
Hospital Clínic de Barcelona
Barcelona, Barcelona [barcelona], Spain
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, , Spain
Hospital Universitario HM Sanchinarro
Madrid, , Spain
Hospital Universitario Virgen de Valme
Seville, , Spain
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch
Taoyuan District, , Taiwan
Royal Marsden Hospital (Chelsea)
London, Kensington and Chelsea, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, , United Kingdom
Royal Cornwall Hospitals NHS Trust
Truro, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509466-38-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
B9991046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.